John Deleon

US Patent:

6727264, Apr 27, 2004

Filed:

Jul 3, 2002

Appl. No.:

10/188434

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ
John Wetzel - Fairlawn NJ
John E. DeLeon - North Bergen NJ
Yu Jiang - Jersey City NJ
Chien-An Chen - Fresh Meadows NY
Kai Lu - Elmwood Park NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

A61K 31445

US Classification:

514323, 514331, 546200, 546234

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

US Patent:

7067534, Jun 27, 2006

Filed:

Nov 21, 2003

Appl. No.:

10/719358

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John Wetzel - Fairlawn NJ, US
John E. DeLeon - North Bergen NJ, US
Yu Jiang - Jersey City NJ, US
Chien-An Chen - Flushing NY, US
Kai Lu - Lake Hiawatha NJ, US

Assignee:

H. Lundbeck A/S - Valby-Copenhagen

International Classification:

A61K 31/445
C07D 401/06

US Classification:

514323, 514331, 546201, 546234

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

US Patent:

20030069261, Apr 10, 2003

Filed:

Jul 5, 2001

Appl. No.:

09/899635

Inventors:

Mohammad Marzabadi - Ridgewood NJ, US
John Wetzel - Fairlawn NJ, US
John DeLeon - North Bergen NJ, US
Bharat Lagu - Belle Mead NJ, US
Charles Gluchowski - Danville CA, US
Stewart Noble - Lake Forest IL, US
Dhanapalan Nagarathnam - Bethany CT, US

International Classification:

A61K031/513
C07D239/24

US Classification:

514/269000, 544/316000

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

US Patent:

20040242609, Dec 2, 2004

Filed:

Apr 15, 2004

Appl. No.:

10/825643

Inventors:

Mohammad Marzabadi - Ridgewood NJ, US
John Wetzel - Fairlawn NJ, US
John Deleon - North Bergen NJ, US
Bharat Lagu - Belle Mead NJ, US
Charles Gluchowski - Danville CA, US
Stewart Noble - Lake Forest IL, US
Dhanapalan Nagarathnam - Bethany CT, US

Assignee:

Synaptic Pharmaceutical Corporation

International Classification:

A61K031/513
C07D239/02

US Classification:

514/269000, 544/316000

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

US Patent:

20050154020, Jul 14, 2005

Filed:

Jan 14, 2004

Appl. No.:

10/757962

Inventors:

Mohammad Marzabadi - Ridgewood NJ, US
John Wetzel - Fair Lawn NJ, US
Chien-An Chen - Flushing NY, US
John Deleon - North Bergen NJ, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Elmwood Park NJ, US

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

A61K031/4545
C07D041/14

US Classification:

514318000, 546194000

Abstract:

This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

US Patent:

20050154022, Jul 14, 2005

Filed:

Jan 13, 2005

Appl. No.:

11/034611

Inventors:

Mohammad Marzabadi - Ridgewood NJ, US
John Wetzel - Fairlawn NJ, US
Chien-An Chen - Flushing NY, US
John DeLeon - North Bergen NJ, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US

International Classification:

A61K031/4545
C07D041/14

US Classification:

514318000, 546194000

Abstract:

This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

US Patent:

20070043080, Feb 22, 2007

Filed:

Aug 30, 2005

Appl. No.:

11/214968

Inventors:

Mohammad Marzabadi - Ridgewood NJ, US
John Wetzel - Fair Lawn NJ, US
John DeLeon - North Bergen NJ, US
Yu Jiang - Jersey City NJ, US
Chien-An Chen - Flushing NY, US
Kai Lu - Lake Hiawatha NJ, US

International Classification:

A61K 31/445
C07D 211/26

US Classification:

514317000, 546229000

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.